feron-␥ release assays for active pulmonary TB diagnosis in low-and middle-income countries. All existing tests for latent TB infection appear to have only modest predictive value and further research is needed to identify highly predictive biomarkers.
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Med Princ Pract 2012;21:4-13 5 tion of Mycobacterium tuberculosis (MTB) using microscopy, growth and isolation of MTB (using culture) and amplification and detection of MTB nucleic acids (nucleic acid amplification tests, NAAT). While microscopy, culture and NAATs are commonly used, each has its strengths and limitations. For latent TB infection (LTBI), the diagnostic options have always been immune-based, given that none of the three options (i.e. smears, culture, NAAT) for active TB work for LTBI. Broadly, immunodiagnostics for TB can be grouped into two categories ( fig. 1 
Serological (Antibody) Assays for Active TB Diagnosis
Serological assays have been in use for many years, although no international guideline has recommended their use. In fact, the International Standards for TB Care discourage the use of these tests [4] . These assays are commercially available in two formats: ELISA-based laboratory assays; and rapid immunochromatographic tests intended to be used as point-of-care (POC) tests. A large number of studies have evaluated the performance of serological tests, and these have been summarized in systematic reviews [5, 6] . In addition, UNICEF/UNDP/ World Bank/World Health Organization (WHO) Special Programme for Research and Training in Tropical Diseases recently published an evaluation of 19 commercially available rapid serological tests for TB [7] .
Available evidence, summarized in table 1 , clearly shows that serological tests for TB are inaccurate (with highly inconsistent estimates of sensitivity and specificity) and that there is no evidence that these tests improve patient outcomes. In fact, because of false-negative and false-positive results, patients can be misdiagnosed, causing harm, diagnostic delays, morbidity and mortality [8] . Despite this evidence, dozens of different serological tests are sold and used in countries with weak regulatory systems, including countries such as India, China, Brazil, South Africa, Pakistan, Bangladesh and Indonesia. Recent reports in the media have highlighted the case of India, where an estimated 1.5 million TB serological (ELISA) tests are done every year (mostly in the private sector) at an expenditure conservatively estimated at USD 15 million per year [8, 9] . Media reports have also emphasized the fact that serological kits are not approved for use in the high-income countries (e.g. France, UK, USA, Canada, Australia, Japan), where they have been developed, and instead are exported to low-and middleincome countries with weak regulatory systems [9] . For example, anda-TB (Anda Biologicals, Strasbourg, France) and Pathozyme TB (Omega Diagnostics Ltd, Alva, Scotland, UK) are the most commonly used serological tests in Indian private laboratories, and they are exported from companies in France and Scotland, UK, respectively, where these tests are not clinically used.
Recognizing the potential harm posed by these suboptimal tests, the WHO convened an Expert Group in July 2010 to review the evidence on TB serological tests. Based on published evidence and expert opinion, the WHO Expert Group concluded that commercial serological tests provide inconsistent and imprecise estimates of sensitivity and specificity. There is no evidence that existing commercial serological assays improve patient-important outcomes. Overall data quality was graded as very low and the Expert Group strongly recommended against the use of these tests for the diagnosis of pulmonary and extra-pulmonary TB [10] . On 27 September 2010, this recommendation was approved by STAG-TB, the highest policy making body for TB at WHO [10] . A negative WHO policy on TB serology was published in July 2011 [10] , as highlighted by a recent Lancet World Report which provided an insightful analysis of the situation [9] . The WHO policy does not discourage research in serological tests. In fact, the WHO strongly encourages research because immunological discovery research may eventually produce tests that may be helpful as POC rapid tests that are currently missing in the TB diagnostics pipeline [9] .
IGRAs for Latent TB Diagnosis
The development of IGRAs has been a recent advance in the diagnosis of LTBI. IGRAs are in vitro blood tests of cell-mediated immune response; they measure T cell release of IFN-␥ following stimulation by antigens that are unique to MTB, including early secreted antigenic target 6 (ESAT-6) and culture filtrate protein 10 (CFP10). These antigens are more specific for TB than purified protein derivative because they are not shared with any BCG vaccine strains or certain species of nontuberculous mycobacteria (e.g. M. avium ) [11] . Two IGRAs are available in many countries: the QuantiFERON-TB © Gold In-Tube (QFT-GIT) assay (Cellestis Ltd., Vic., Australia) and the T-SPOT.TB © assay (Oxford Immunotec, Abingdon, UK). Both tests are approved by the US Food and Drug Administration, and are also available in Europe and many other countries.
A large number of studies have evaluated IGRAs and based on several systematic reviews and recently updated guidelines [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] , the following summary points can be made about their accuracy, performance and operational characteristics (summarized in table 2 ):
IGRAs, like the TST, are surrogate markers of MTB infection. They indicate a cellular immune response to recent or remote sensitization with MTB. Therefore, in their current format, IGRAs cannot distinguish between latent infection and active TB disease [27] . Similar to the TST, a positive IGRA result may not necessarily indicate active TB and similarly, a negative IGRA result may not rule out active disease in persons with suspected TB [25, 27] . Specificity of IGRAs is poor in patients with suspected active TB in high TB burden settings, and this suggests that IGRAs may not be useful as a rule-in test for active TB in TB endemic countries with a high background prevalence of LTBI [25, 27] . Overall, IGRAs and TST are not intended for active TB diagnosis in adults [25, 27, 29] . Indeed, a recent WHO recommendation reinforces this message [10] .
IGRAs have excellent specificity ( 1 95%) for latent TB infection that is not affected by BCG vaccination [13, 25] . Specificity in this context refers to estimates from lowrisk individuals with no known TB exposure in low TB incidence countries. In contrast, the specificity of TST varies across populations depending on timing of BCG and whether repeated (booster) vaccinations are given [30] . For example, some countries recommend booster BCG vaccinations post-infancy and into adolescence and this can compromise the value of TST. IGRAs may be more helpful for LTBI diagnosis in such countries. A World Atlas of BCG Policies and Practices (www.bcgatlas.org) has been recently compiled to help clinicians and public health practitioners better interpret TST and decide on populations where the more specific IGRAs may be more appropriate than the TST [31] . Another webbased resource (www.tstin3d.com) has been developed to facilitate the interpretation of TST as well as IGRAs.
Using culture-confirmed active TB as a surrogate reference standard for latent TB infection, the sensitivity for T-SPOT.TB appears to be higher than QFT-GIT or TST (approximately 90, 80, and 80%, respectively) [25, 27] . The higher sensitivity of T-SPOT.TB may be useful for evaluating individuals with immunosuppressive conditions.
IGRA sensitivity appears to be lower in culture-proven active TB patients in high incidence settings (as compared to sensitivity in low incidence settings) [25, 27] . Thus, a negative IGRA result should not be used to rule out active TB disease [27] .
Just as HIV infection compromises TST performance, HIV infection appears to compromise IGRA sensitivity, and lower CD4 counts are associated with higher rates of indeterminate IGRA results; this is especially the case with QFT-GIT [24, 27] . TSPOT appeared to be relatively less affected by immunosuppression than QFT-GIT and tuberculin skin testing, likely because the testing platform ensures that an adequate number of peripheral blood mononuclear cells are available despite overall low CD4+ cell counts in whole blood [24] .
Both IGRA and TST results correlate well with risk factors and surrogate markers of TB exposure [28] , but the magnitude of the association varies across populations. In most low TB incidence countries, TST results are associated with BCG, while IGRA results are not (and this often results in TST+/IGRA-type of discordant results).
IGRA-positive contacts have a higher incidence of active TB than IGRA-negative contacts, but the association is modest. The majority of those who are IGRA-positive do not seem to progress to active TB disease (this is also true for TST) [32, 33] . In fact, the totality of evidence suggests that all existing LTBI tests (TST and IGRAs) appear to have only modest predictive value and may not help identify those who are at highest risk of progression to TB disease. Based on the evidence thus far, IGRAs appear to have similar predictive value as the TST [32] .
Even among contacts in high TB incidence settings, the majority of those with positive IGRA results do not seem to progress to TB disease, suggesting that IFN-␥ alone may not be sufficient as a prognostic biomarker [32, 33] , especially in high TB burden settings where repeated infections are highly likely. It may be necessary to measure additional biomarkers, or incorporate biomarkers with other known risk factors into a composite risk prediction model.
IGRAs are dynamic tests and conversions and reversions are frequently observed during serial testing [23, 34] . The interpretation of such dynamic IFN-␥ kinetics is Less expensive than IGRAs (reagent cost is substantially less than IGRA kit costs), but personnel time costs will have to be factored, along with time and cost for 2 patient visits No laboratory required Need to establish a program with trained staff to administer and read TST results Staff training is needed to minimize reading errors and variability (under reading, within and between reader variability, digit preference, etc.) PPD must be stored at optimal temperatures Only standardized PPD must be used Need to establish well-equipped laboratory with electricity, which can perform ELISA or ELISPOT Need to procure equipment and supplies for IGRA performance and quality assurance (IGRA reagents' cost higher than TST reagents) Need for staff training, including blood-borne pathogen training Need for cold chain for transport of kits and reagents and for storing them Need for careful handling (e.g. tube shaking) and processing of blood samples (incubation of samples within a specific time window) to ensure accuracy of tests Availability of well-trained staff or staff to be trained BCG = Bacillus Calmette-Guérin vaccine; IPT = isoniazid preventive therapy; PPD = purified protein derivative.
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Available evidence does not support the use of IGRAs for monitoring therapy of active disease or latent TB infection. Monitoring of active TB therapy must continue to rely on sputum smears and culture.
There is some evidence that IGRAs done on specimens from the site of the disease (e.g. broncho-alveolar lavage fluids) may add some diagnostic value in smear-negative TB [25] , but this requires further evaluation. Furthermore, site-specific specimens are not easy to obtain in resource-limited settings.
From an operational perspective, the reagent (kit) costs of IGRAs are substantially higher than costs of TST, and unlike the TST, IGRAs require laboratories with trained staff that can perform ELISA or ELISPOT assays. IGRAs require blood draws and this may be challenging in young children. Errors in collecting, labeling, or transporting blood specimens, or while performing and interpreting these assays, can affect their accuracy. Also, IGRAs require fresh blood samples and transportation delays can affect test performance.
IGRA requires fewer visits than TST for test completion (although follow-up visits will be needed for both tests for initiation of therapy for LTBI) and results can potentially be available in 24-48 h. The risk of adverse events with IGRA may be reduced compared to TST. Unlike the TST, IGRAs can be repeated without the risk of sensitization and boosting. IGRA interpretation is objective, whereas TST interpretation is affected by inter-and intrareader variation. A major challenge for implementing TST is failure of test individuals to return for the reading.
While IGRAs are reliable and fairly robust in field conditions, there are operational issues such as time to incubation, power outages, and tube shaking that must be adequately addressed. Test kits must be transported and stored in optimum conditions to prevent exposure to excessive heat. Strict quality assurance is necessary to detect unusual patterns in results (e.g. spike in numbers of indeterminate results due to low mitogen response). It is critically important to run both positive and negative controls with each assay, and adequate attention must be paid to training of laboratory technicians.
Major Guidelines on IGRAs
The use of IGRAs is increasing in low or intermediate TB incidence countries. More than twenty countries (almost all low TB incidence settings) now have at least one guideline or statement on the use of IGRAs [35, 36] . The only guideline to explicitly address use of IGRAs in lowand middle-income countries with high TB incidence is the recommendation by the WHO [10] .
In these guidelines, three main approaches have been recommended for the use of IGRAs: (1) TST should be replaced by IGRAs; (2) either TST or IGRAs may be used; (3) two-step approach of TST first, followed by IGRA. As seen in table 3 , there is considerable diversity in how various countries currently recommend and use IGRAs [35, 36] . The two-step approach of TST followed by IGRA seems to be the most dominant strategy and this may partly be due to cost considerations. Some European countries (e.g. Germany, Denmark, Switzerland) have strongly favored the use of IGRAs in individuals on immunosuppressive medications such as TNF-␣ blockers.
Gaps in the TB Diagnostics Pipeline and Future Prospects for Improved Tests
In recent years, considerable improvements have been made in TB diagnostics (and information has been summarized and made easily accessible through a new website www.tbevidence.org, by the Stop TB Partnership) and the current pipeline ( fig. 2 ) is a significant improvement over the situation in the past [19, 33] . However, there are two major gaps in the existing diagnostics pipeline: lack of a simple accurate POC test for TB that can be used for rapid diagnosis at the primary care level; lack of a biomarker (or combination of biomarkers) that can be used to accurately identify latently infected individuals who will benefit most from preventive therapy. The Stop TB Partnership's New Diagnostics Working Group anticipates that a POC test for active TB may become available by 2013, and a LTBI predictive biomarker test may become available by 2015, and these goals ( fig. 2 ) are now incorporated into the revised Global Plan to Stop TB (2011-2015) [37] .
At present, the only assay that comes close to being a POC test is the Xpert © MTB/RIF assay (Cepheid Inc, Sunnyvale, Calif., USA) for rapid molecular diagnosis of TB [38] . On December 8th, 2010, the WHO announced its endorsement/approval of this cartridge-based automated NAAT test, which can accurately detect TB and rifampin resistance in less than 2 h with minimal handson technical time [39] . Preliminary studies of this system suggest diagnostic performance comparable to culture, the current gold standard [38] . The Xpert MTB/RIF assay is a fully integrated and automated system that is IGRAs can be used in place of (but not in addition to) TST in all situations in which CDC recommends TST as an aid in diagnosing MTB infection with preferences and special considerations. This includes contact investigations, testing during pregnancy, and screening of health care workers and others undergoing serial evaluation for MTB infection. Despite the indication of a preference, use of the alternative test (FDA-approved IGRA or TST) is acceptable in medical and public health practice. Populations in which IGRAs are preferred for testing: -Persons who have received BCG (either as a vaccine or for cancer therapy); and -Persons from groups that historically have poor rates of return for TST reading. TST is preferred over IGRAs for testing children less than 5 years of age.
Canada
Canadian Tuberculosis Committee, 2010 [17] IGRAs are not recommended for the diagnosis of active TB in adults.
Evidence of TB infection in children is often used in making a diagnosis of active TB, in addition to symptoms, radiological abnormalities, history of exposure, and microbiological investigations such as microscopy and culture. IGRAs should not be used as a replacement for conventional microbiological diagnosis of pulmonary and extra-pulmonary TB in low-and middle-income countries simple to perform with minimal training, is not prone to cross-contamination, requires minimal biosafety facilities, and has a high sensitivity in smear-negative TB. Thus, the assay can be placed closer to the patients, in a clinic setting without the need for laboratory infrastructure [40] . The GeneXpert platform can be used for a variety of disease conditions, including health-care associated infections such as Clostridium difficile and methicillin-resistant Staphylococcus aureus . In the policy roadmap released in December 2010 [39] , the WHO Expert Group recommended that: Xpert MTB/ RIF should be used as the initial diagnostic test in individuals suspected of MDR-TB or HIV-associated TB (strong recommendation); Xpert MTB/RIF may be used as a follow-on test to microscopy in settings where MDR and/or HIV is of lesser concern, especially in smear-negative specimens (conditional recommendation, recognizing major resource implications). These recommendations have been backed by volume-based price reductions to make the test more affordable [39] . Efforts are currently underway to scale up this technology, although cost still remains a major barrier for scale-up [40] . In addition to high cost, other potential limitations include the need for continuous electricity, stable temperature, storage facilities and equipment maintenance.
Substantial investments are being made in meeting the Global Plan goals for diagnostics, including biomarker research [33] , novel antigen discovery [41] , use of combination of antigens to improve performance [42] , and exploitation of technologies such as high-throughput detection of antibodies to the entire MTB proteome [43] and transcriptional biomarkers with potential as diagnostic tools [44] . Also, newer studies on the Xpert MTB/ RIF technology suggest great promise [45] [46] [47] [48] , and could potentially have a big impact if they can be used to replace ineffective serological tests in high-burden countries [49] . Thanks to these efforts, the next few years should see exciting advances that will complete the TB diagnostics pipeline, and help control TB. However, product development will not by itself result in public health impact. The impact of new tests will depend on the manner and extent of their introduction and scale-up, the strength of the laboratories in which they are used, and the degree to which access to appropriate therapy follows access to diagnosis. Translation of scientific progress into real impact is critical, and may be possible with political commitment, increased funding and engagement of all stakeholders.
